Famcitech Tablet 250mg (Famciclovir)

Adult dosage

1. Treatment of herpes zoster Adults: Administer famciclovir 250 mg per dose orally 3 times daily for 7 days. It is preferable to start treatment as soon as symptoms appear after infection. 2. Treatment of first-episode genital herpes Adults: Administer 250 mg of this medicine per dose orally 3 times daily for 5 days. It is preferable to start treatment as soon as symptoms appear after infection. 3. Treatment of acute recurrent genital herpes Adults: Administer 125 mg of this medicine per dose orally 2 times daily for 5 days. It is preferable to start treatment during the prodromal period or as soon as symptoms appear after infection. 4. Suppression of recurrent genital herpes Adults: Administer 250 mg of this medicine per dose orally 2 times daily. Discontinue treatment periodically every 6～12 months to observe whether the natural course of the disease has changed. 5. Patients with renal impairment: Because clearance of this medicine is reduced in patients with renal impairment, dose adjustment should be made with caution. The dosage for these patients is as follows. 1) Treatment of herpes zoster and first-episode genital herpes: Creatinine clearance (mL/min/1.73㎡) 30～59: 250 mg per dose 2 times daily 10～29: 250 mg per dose once daily 2) Treatment of acute recurrent genital herpes: Creatinine clearance (mL/min/1.73㎡) 30～59: 125 mg per dose 2 times daily 10～29: 125 mg per dose once daily 3) Suppression of recurrent genital herpes: Creatinine clearance (mL/min/1.73㎡) 30～59: 250 mg per dose 2 times daily 10～29: 125 mg per dose 2 times daily 4) If only serum creatinine is known, creatinine clearance can be calculated using the following formula. Men: {body weight (kg) × (140-age)}/ {72 × serum creatinine (mg/dL)} Women: 0.85 × the value calculated for men 5) Patients with renal impairment undergoing hemodialysis For patients undergoing hemodialysis, administration every 48 hours is preferable, taking the dialysis interval into account. Four hours of hemodialysis reduces the plasma concentration of this medicine by approximately 75%; therefore, administer this medicine immediately after dialysis. The recommended dose is 250mg for patients with herpes zoster and 125mg for patients with genital herpes. 6. Patients with hepatic impairment: No dose adjustment is required in patients with chronic compensated liver disease. There is insufficient treatment experience in patients with overt chronic decompensated liver disease; therefore, no clear recommended dose has been established.

This medication should not be used by patients who have had hypersensitivity reactions to specific ingredients. Additionally, this medication contains lactose, so individuals with galactose intolerance, lactase deficiency, or glucose-galactose malabsorption should not take it. Patients with impaired kidney function should use this medication with special caution. While taking this medication, symptoms like headache and nausea may occur, but they are usually mild to moderate. Rarely, thrombocytopenia or leukopenia may occur, and dizziness, drowsiness, or hallucinations have been reported. Gastrointestinal issues such as nausea, vomiting, abdominal pain, and diarrhea may commonly appear, and abnormalities in liver function, skin rashes, or itching may also occur. Acute renal failure has been rarely reported in patients with poor kidney function. This medication does not completely cure genital herpes, so it is recommended to avoid sexual contact when symptoms are present during treatment. It is advisable to maintain safe sexual practices once treatment begins, and to initiate treatment immediately if recurrent symptoms arise. There is no evidence that this medication affects driving or machine operation, but if dizziness, drowsiness, or confusion occurs, it is advisable to refrain from driving or operating machinery. Patients with mild to moderate liver impairment do not require special dosage adjustments, but the safety in severe liver impairment has not been established. This medication has a low potential for interactions with other drugs; however, caution is needed when taken with specific medications like probenecid, which may increase blood concentrations. Additionally, it may reduce effectiveness when taken concurrently with lamotrigine, so treatment effects should be closely monitored. Safety has not been thoroughly established during pregnancy; therefore, women who are pregnant or may become pregnant should take it with caution after consultation with their physician. Women who are breastfeeding should also be cautious of the potential for excretion in breast milk and should only use it when the benefits outweigh the risks. This medication is not recommended for children under 18, as its safety and effectiveness have not been established. Generally, elderly patients do not require dosage adjustments, but dosage adjustments may be needed if kidney function is impaired. In case of overdose, appropriate supportive therapy and symptomatic treatment should be provided, and blood dialysis may help reduce drug concentrations. This medication should be stored in a closed container, as it is sensitive to air and moisture. Additionally, it is important to store it in a cool, dry place below 30 degrees Celsius to maintain its efficacy. It should be stored out of reach of children. Transferring to another container is not advisable as it may compromise quality.

• Headache
• nausea
• thrombocytopenia
• leukopenia
• neutropenia
• dizziness
• confusion
• drowsiness
• hallucination
• palpitations

This medication is sensitive to air and moisture, so it should be stored in a sealed container. It is also important to store it in a cool and dry place below 30 degrees Celsius to maintain its efficacy.

Appearance

White round film-coated tablet

Package unit

21 tablets (7 tablets/PTP x 3)